Apollomics Inc - Class A
Research Apollomics Inc - Class A (APLM) on Bullrun: market cap USD 58.20M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerAPLM
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 58.20M
- Financial periodQ4 2025
Valuation Snapshot
latest market cap is USD 58.20M.
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 58.20M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 40.13M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 10.75M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 86.35M | n/a | n/a | n/a |
About Apollomics Inc - Class A
Apollomics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of oncology therapies to harness the immune system and target specific molecular pathways to inhibit cancer. The company's products portfolio includes Vebreltinib (APL-101), an oral active, highly selective c-Met inhibitor, which is in Phase 2 clinical trials for treatment of non-small cell lung cancer and other solid tumors with MET dysregulation;
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Apollomics Inc - Class A's market cap?
Apollomics Inc - Class A's market capitalization is USD 58.20M.
What does Apollomics Inc - Class A do?
Apollomics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of oncology therapies to harness the immune system and target specific molecular pathways to inhibit cancer. The company's products portfolio includes Vebreltinib (APL-101), an oral active, highly selective c-Met inhibitor, which is in Phase 2 clinical trials for treatment of non-small cell lung cancer and other solid tumors with MET dysregulation; and APL-102, an oral active, small molecule multiple tyrosine kinase inhibitor, which is in a in a Phase 1 clinical trial for cancer treatment.